Electronic Supplementary Material (ESI) for RSC Advances. This journal is © The Royal Society of Chemistry 2017

Supporting Information for:

Efficient Asymmetric Hydrophosphonylation of Unsaturated Amides Catalyzed by Rare-Earth Metal Amides [(Me₃Si)₂N]₃RE(*m*-Cl)Li(THF)₃ with Phenoxy-Functionalized Chiral Prolinols

Zenghui Fei^a, Chao Zeng^a, Chengrong Lu^a, Bei Zhao ^{a, *} and Yingming Yao ^{a, *}

Table of contents

Page
2
3
3
4
8
15
56

^{*} Corresponding author. Tel.: +86 512 65880305; fax: +86 512 65880305; e-mail: zhaobei@suda.edu.cn

^{*} Corresponding author. e-mail: yaoym@suda.edu.cn

General Methods

All reagents are commercially available, reagent grade, and used as received unless otherwise noted. The reactions involving air and water sensitive components were performed with the standard Schlenk techniques. Solvents, such as THF, toluene and hexane, were degassed and distilled from sodium benzophenone ketyl before use.

Analytical thin layer chromatography (TLC) was performed using F254 pre-coated silica gel plate (0.2 mm thickness). After elution, plates were detected using UV radiation (254 nm) on a UV lamp.

Flash chromatography was performed using 200-300 mesh silica gel with freshly distilled solvents. Columns were typically packed as slurry and equilibrated with the appropriate solvent system prior to use.

Nuclear magnetic resonance spectra were obtained on a Bruker AV-400 apparatus (CDCl₃ as solvent). Chemical shifts for NMR spectra are reported as δ in units of parts per million (ppm) downfield from SiMe₄ (δ 0.0) and relative to the signal of chloroform-d (δ 7.26, singlet). Multiplicities were given as: s (singlet); d (doublet); t (triplet); q (quartet); dd (doublets of doublet); or m (multiplets).

High Resolution Mass (HRMS) spectra were obtained using Bruker ESI-TOF.

The ee values determination was carried out using HPLC (Agilent Technologies 1200 Series) with Daicel Chiralcel columns at 23-25 °C. Optical rotation was measured using an Autopol IV Polarimeter equipped with a sodium vapor lamp at 589 nm. The absolute configuration of **7a** was determined by the combination of single crystal diffraction, chiral HPLC and the optical rotation analysis. Hence, **7b-7t** were assigned by analogy, assuming the same reaction pathway and the same analysis.

Rare earth metal analysis was performed by EDTA titration with a xylenol orange indicator and a hexamine buffer. Carbon, hydrogen and nitrogen analyses were performed by direct combustion with a Carlo-Erba EA-1110 instrument.

Suitable single crystals of complex **8** was sealed in a thin-walled glass capillary for determining the single-crystal structure. Intensity data were collected with a Rigaku Mercury CCD area detector in ω scan mode using Mo-K α radiation ($\lambda = 0.71075$ Å). The diffracted intensities were corrected for Lorentz polarization effects and empirical absorption corrections. Details of the intensity data collection and crystal data are given in Table 1. All the non-hydrogen atoms were refined anisotropically. All the H atoms were held stationary and included in the structure factor calculation in the final stage of full-matrix least-squares refinement. The structures were solved and refined using SHELEXL-97 programs.

Experimental section: General Procedure for the Preparation of the Rare-Earth Metal Complex 8¹:



Table 1 Crystallographic Data for Complex 8

Compound	8	Compound	8
Formula	$C_{84}H_{87}N_2O_4Sc$	F(000)	2632
fw	1233.52	$\theta_{ m max}/^{\circ}$	27.50
Crystal system	Orthorhombic	Collected	44528
Crystal size/mm	$0.40 \times 0.20 \times 0.20$	Unique reflns	20922
Space group	P 21 21 21	Obsd reflns, $[I > 2.0 \sigma(I)]$	17160
a/Å	13.546	No. of variables	832
$b/{ m \AA}$	24.517	GOF	1.008
$c/{ m \AA}$	27.817	R	0.0651
$V/Å^3$	9237.9	wR	0.1600
Ζ	4	R _{int}	0.0466
$D_{\rm calcd}/{ m g~cm^{-3}}$	0.887	Largest diff. peak, hole/e Å ⁻³	0.384,-0.281
μ/mm^{-1}	0.119		

X-Ray Structures of Complex 8 and selected bond lengths and bond angles

Crystals of complex **8** suitable for X-ray diffraction were obtained in toluene and hexane at room temperature. The definitive structure is shown in Figure 1, and the corresponding selected bond lengths and angles are provided in the figure captions.



Figure 1. Molecular structure of 8 showing 20% probability ellipsoids. Hydrogen atoms are omitted for clarity. Selected bond lengths (Å) and bond angles (o): Sc(1)-O(1) 2.0350(16), Sc(1)-O(2) 1.9518(17), Sc(1)-O(3) 2.0141(16), Sc(1)-O(4) 1.9833(16), Sc(1)-N(2) 2.3539(19), O(2)-Sc(1)-O(4) 108.05(7), O(2)-Sc(1)-O(3) 115.27(7), O(4)-Sc(1)-O(3) 132.87(7), O(2)-Sc(1)-O(1) 97.92(7), O(4)-Sc(1)-O(1) 99.48(7), O(2)-Sc(1)-O(1) 92.29(6), O(2)-Sc(1)-N(2) 99.29(7), O(4)-Sc(1)-N(2) 74.83(7), O(3)-Sc(1)-N(2) 80.64(7), O(1)-Sc(1)-N(2) 162.78(7).

General procedure for the synthesis of the substrates 6a-6t and their characterization data

To a dichloromethane solution of 16 mmol substituted amine and 16 mmol Et₃N, a substituted unsaturated acyl chloride was added dropwise, keeping the reaction temperature at 0 °C. The mixture was continued to stir for 2 h at room temperature, then aqueous NaHCO₃ (25 mL) was added. The crude product was extracted with DCM (3 x 50 mL). The combined organic layers were washed with 1M HCl (3 x 20 mL) and brine (3 x 20 mL) and dried over Na₂SO₄. Solvent was removed in vacuo, then the crude product was purified by column chromatography (ethyl acetate-petroleum ether, 1:10)².



Characterization data as follows:



N-benzylcinnamamide (6a): White solid. ¹H NMR (400 MHz, CDCl₃): δ 7.67 (d, *J* = 13.80 Hz, 1H, CH=CH), 7.48 (m, 2H, Ph), 7.34 (m, 8H, Ph), 6.46 (d, *J* = 15.60 Hz, 1H, CH=CH), 5.89 (s, 1H, NH), 4.57 (d, *J* = 5.72 Hz, 2H, CH₂).



N-butylcinnamamide (6b): White solid. ¹H NMR (400 MHz, CDCl₃): δ 7.61 (d, J = 15.60 Hz,

1H, CH=CH), 7.33 (m, 3H, Ph), 6.38 (d, *J* = 15.60 Hz, 1H, CH=CH), 5.67 (s, 1H, NH), 3.37 (m, 2H, CH₂), 1.53 (m, 2H, CH₂), 1.36 (m, 2H, CH₂), 0.92 (t, *J* = 14.64 Hz, 3H, CH₃).



N-isopropylcinnamamide (6c): White solid. ¹H NMR(400 MHz, CDCl₃): δ 7.61 (d, J = 15.60 Hz, 1H, CH=CH), 7.45 (m, 2H, Ph), 7.30 (m, 3H, Ph), 6.41 (d, J = 15.60 Hz, 1H, CH=CH), 5.83 (d, J = 6.08 Hz, 1H, NH), 4.21 (m, 1H, CH), 1.18 (d, J = 6.56 Hz, 6H, CH₃).



N-phenylcinnamamide (6d): White solid. ¹H NMR(400 MHz, CDCl₃): δ 7.92 (s, 1H, NH), 7.74 (d, *J* = 15.52 Hz, 1H, CH=CH), 7.65 (m, 2H, Ph), 7.45 (m, 2H, Ph), 7.32 (m, 5H, Ph), 7.11 (m, 1H, Ph), 6.63 (d, *J* = 15.52 Hz, 1H, CH=CH).



N-(o-tolyl)cinnamamide (6e): White solid. ¹H NMR(400 MHz, CDCl₃): δ 7.95 (s, 1H, NH), 7.76 (d, *J* = 15.52 Hz, 1H, CH=CH), 7.52 (m, 2H, Ph), 7.36 (m, 3H, Ph), 7.19 (m, 2H, Ph), 7.10 (m, 2H, Ph), 6.58 (d, *J* = 15.64 Hz, 1H, CH=CH).



N-(p-tolyl)cinnamamide (6f): White solid. ¹H NMR(400 MHz, CDCl₃): δ 8.12 (s, 1H, NH), 7.64 (d, *J* = 15.56 Hz, 1H, CH=CH), 7.46 (m, 2H, Ph), 7.33 (m, 2H, Ph), 7.20 (m, 3H, Ph), 7.01 (m, 2H, Ph), 6.56 (d, *J* = 15.52 Hz, 1H, CH=CH), 2.19 (s, 1H, CH₃).



N-(2-methoxyphenyl)cinnamamide (6g): White solid. ¹H NMR(400 MHz, CDCl₃): δ 8.51 (m, 1H, Ph), 7.93 (s, 1H, NH), 7.74 (d, *J* = 15.48 Hz, 1H, CH=CH), 7.55 (m, 2H, Ph), 7.37 (m, 3H, Ph), 7.00 (m, 2H, Ph), 6.87 (m, 1H, Ph), 6.59 (d, *J* = 15.52 Hz, 1H, CH=CH), 3.90 (s, 3H, CH₃).



N-(4-methoxyphenyl)cinnamamide (6h): White solid. ¹H NMR(400 MHz, CDCl₃): δ 7.78 (s, 1H, NH), 7.72 (d, *J* = 15.48 Hz, 1H, CH=CH), 7.53 (m, 4H, Ph), 7.31 (m, 3H, Ph), 6.82 (m, 2H, Ph), 6.54 (d, *J* = 15.52 Hz, 1H, CH=CH), 3.75 (s, 3H, CH₃).



N-(3-chlorophenyl)cinnamamide (6i): White solid. ¹H NMR(400 MHz, CDCl₃): δ 7.85 (s, 1H, NH), 7.76 (m, 2H, Ph, CH=CH), 7.50 (m, 3H, Ph), 7.34 (m, 3H, Ph), 7.23 (m, 1H, Ph), 7.09 (m, 1H, Ph), 6.60 (d, *J* = 15.52 Hz, 1H, CH=CH).



N-(4-fluorophenyl)cinnamamide (6j): White solid. ¹H NMR(400 MHz, CDCl₃): δ 7.75 (d, *J* = 15.48 Hz, 1H, CH=CH), 7.56 (m, 4H, Ph), 7.37 (m, 3H, Ph), 7.02 (m, 2H, Ph), 6.53 (d, *J* = 15.52 Hz, 1H, CH=CH).



N-(4-(trifluoromethyl)phenyl)cinnamamide (6k): White solid. ¹H NMR(400 MHz, CDCl₃): δ 7.79 (s, 1H, NH), 7.72 (m, 2H, Ph, CH=CH), 7.59 (m, 2H, Ph), 7.49 (m, 3H, Ph), 7.38 (m, 3H, Ph), 6.55 (d, *J* = 15.48 Hz, 1H, CH=CH).



(E)-N-(4-methoxyphenyl)but-2-enamide (61): White solid. ¹H NMR(400 MHz, CDCl₃): δ 7.55 (m, 3H, Ph, NH), 6.83 (m, 3H, Ph, CH=CH), 5.96 (d, J = 15.08 Hz, CH=CH, 1H), 3.77(s, 3H, CH₃), 1.85 (d, J = 5.44 Hz, 3H, CH₃).



(E)-N-phenyl-3-(p-tolyl)acrylamide (6m): White solid. ¹H NMR(400 MHz, CDCl₃): δ 7.73 (m, d, *J* = 15.48 Hz, 1H, CH=CH), 7.61 (m, 2H, Ph), 7.43 (s, 1H, NH), 7.38 (m, 2H, Ph), 7.32 (m, 2H, Ph), 7.16 (m, 3H, Ph), 6.52 (d, *J* = 15.48 Hz, 1H, CH=CH), 2.35 (s, 3H, CH₃).



(E)-3-(3-chlorophenyl)-N-phenylacrylamide (6n): White solid. ¹H NMR(400 MHz, CDCl₃): δ 7.68 (m, d, *J* = 15.48 Hz, 1H, CH=CH), 7.61(m, 2H, NH, Ph), 7.49 (m, 2H, Ph), 7.31 (m, 5H, Ph), 7.12 (m, 1H, Ph), 6.56 (d, *J* = 15.48 Hz, 1H, CH=CH).



(E)-3-(2-fluorophenyl)-N-phenylacrylamide (60): White solid. ¹H NMR(400 MHz, CDCl₃):8782 (m, d, *J* = 15.48 Hz, 1H, CH=CH), 7.60(m, 2H, NH, Ph), 7.44 (m, 2H, Ph), 7.34 (m, 3H, Ph), 7.14 (m, 3H, Ph), 6.71 (d, *J* = 15.72 Hz, 1H, CH=CH).



(E)-3-(4-fluorophenyl)-N-phenylacrylamide (6p): White solid. ¹H NMR(400 MHz, CDCl₃): δ 7.72 (m, d, *J* = 15.48 Hz, 1H, CH=CH), 7.60 (m, 2H, NH, Ph), 7.50 (m, 2H, Ph), 7.33 (m, 3H, Ph), 7.05 (m, 3H, Ph), 6.47 (d, *J* = 15.48 Hz, 1H, CH=CH).



N-benzyl-N-methylcinnamamide (6q): White solid. ¹H NMR(400 MHz, CDCl₃): δ 7.67 (m, d, *J* = 15.32 Hz, 1H, CH=CH), 7.49 (m, 1H, Ph), 7.38 (m, 1H, Ph), 7.25 (m, 8H, Ph), 6.94 (d, *J* = 15.36 Hz, 1H, CH=CH), 4.84 (m, 2H, CH₂), 2.94 (m, 3H, CH₃).



(E)-3-phenyl-1-(pyrrolidin-1-yl)prop-2-en-1-one (6r): White solid. ¹H NMR (400 MHz, CDCl₃): δ 7.70 (d, *J* = 13.80 Hz, 1H, CH=CH), 7.52 (m, 2H, Ph), 7.35 (m, 3H, Ph), 6.73 (d, *J* = 15.52 Hz, 1H, CH=CH), 3.63 (m, 4H, CH₂), 1.99 (m, 2H, CH₂), 1.88 (m, 2H, CH₂).



(E)-3-phenyl-1-(piperidin-1-yl)prop-2-en-1-one (6s): White solid. ¹H NMR (400 MHz, CDCl₃): δ 7.61 (d, *J* = 15.48 Hz, 1H, CH=CH), 7.52 (m, 2H, Ph), 7.34 (m, 3H, Ph), 6.91 (d, *J* = 15.48 Hz, 1H, CH=CH), 3.66 (m, 4H, CH₂), 1.67 (m, 2H, CH₂), 1.60 (m, 4H, CH₂).



N-methyl-N-phenylcinnamamide (6t): White solid. ¹H NMR (400 MHz, CDCl₃): δ 7.72 (d, J = 15.40 Hz, 1H, CH=CH), 7.23 (m, 10H, Ph), 6.41 (d, J = 15.12 Hz, 1H, CH=CH), 3.38 (s, 3H, CH₃).

General procedure for the synthesis of the substrates 7a-7t and their characterization data Scandium amide $[(Me_3Si)_2N]_3Sc(\mu-Cl)Li(THF)_3$ (0.05mmol, 39.15 mg) was added to a stirred solution of H₂L² (0.10 mmol, 59.50 mg) in THF (1 mL) under argon atmosphere. The mixture was stirred at room temperature for 1 h. Then, HPO(OEt)₂ (1.00 mmol, 129 µL) was added in the above solution and stirred for 10 min. After that, unsaturated amide (0.5 mmol, 118 mg) was added to the mixture. The reaction system was stirred for further 12 h at room temperature, quenched by water. The crude product was purified by column chromatography (ethyl acetatepetroleum ether, 1:10) to obtain the final hydrophosphonylation product. The enantiomeric excess of hydrophosphonylation was determined by chiral HPLC analysis.



Characterization data as follows:



(*S*)-diethyl (3-(benzylamino)-3-oxo-1-phenylpropyl)phosphonate (7a): A white powder: yield 99%; $[\alpha]_D^{24} = 12^{\circ}$ (*c* 0.4, CH₃OH); ¹H NMR (400 MHz, CDCl₃): δ 7.71 (m, 1H, NH), 7.34 (m, 2H, Ph), 7.18 (m, 3H, Ph), 7.02 (m, 3H, Ph), 6.78 (m, 2H, Ph), 4.28 (m, 1H, CH), 4.03 (m, 1H, CH), 3.84 (m, 2H, CH₂), 3.75 (m, 2H, CH₂), 3.62 (m, 1H, CH), 3.44 (m, 1H, CH), 3.06 (m, 2H, CH₂), 1.11 (t, *J* = 14.00 Hz, 3H, CH₃), 0.85 (t, *J* = 15.30 Hz, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃): δ 169.65, 137.96, 134.75, 128.99, 127.97, 127.73, 126.85, 126.29, 62.63, 61.55, 42.62, 40.54, 35.97, 15.86; ³¹P NMR (162 MHz, CDCl₃): δ 28.03; 85% *ee*, HPLC: IA, 90% hexanes, 10% /PrOH, 1.0 mL/min, 12.1 min (major), 17.7 min (minor); HRMS (ESI, positive) m/z calcd. for C₂₀H₂₆NO₄P [M+H]⁺ 376.1678; found 376.1670.



(*S*)-diethyl (3-(butylamino)-3-oxo-1-phenylpropyl)phosphonate (7b): Colorless oil: yield 90%; $[\alpha]_D^{24} = 15^{\circ}$ (*c* 0.5, CH₃OH); ¹H NMR (400 MHz, CDCl₃): δ 7.40 (m, 2H, Ph), 7.29 (m, 3H, Ph), 4.06 (m, 2H, CH₂), 3.79 (m, 2H, CH₂), 3.62 (m, 1H, CH), 3.13 (m, 1H, CH), 3.01 (m, 3H, CH₂), 1.31 (t, *J* = 13.84 Hz, 3H, CH₃), 1.25 (m, 2H, CH₂), 1.10 (m, 2H, CH₂), 1.03 (t, *J* = 13.80 Hz, 3H, CH₃), 0.77 (t, *J* = 14.28 Hz, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃): δ 169.33, 134.99, 134.92, 128.80, 127.94, 126.81, 62.45, 61.49, 40.58, 38.61, 36.44, 30.87, 19.29, 15.63, 13.15; ³¹P NMR (162 MHz, CDCl₃): δ 28.50; 75% *ee*, HPLC: IA, 90% hexanes, 10% ⁱPrOH, 1.0 mL/min, 7.9 min (major), 8.6 min (minor); HRMS (ESI, positive) m/z calcd. for C₁₇H₂₈NO₄P [M+H]⁺ 342.1834; found 342.1847.



(*S*)-diethyl (3-(isopropylamino)-3-oxo-1-phenylpropyl)phosphonate (7c): Colorless oil : yield 83%; $[\alpha]_D^{24} = 17^\circ$ (*c* 0.5, CH₃OH); ¹H NMR (400 MHz, CDCl₃): δ 7.36 (m, 2H, Ph), 7.27 (m, 2H, Ph), 7.21 (m, 1H, Ph), 5.54 (d, *J* = 7.00 Hz, 1H, NH), 4.07 (m, 2H, CH₂), 3.88 (m, 2H, CH₂), 3.69 (m, 2H, CH₂), 2.92 (m, 1H, CH), 2.69 (m, 1H, CH), 1.28 (d, *J* = 14.00 Hz, 3H, CH₃), 1.04 (m, 6H, CH₃), 0.80 (d, *J* = 6.5 Hz, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃): δ 168.99, 135.36, 129.37, 128.31, 127.21, 63.00, 61.97, 41.15, 39.76, 36.87, 22.30, 16.39; ³¹P NMR (162 MHz, CDCl₃): δ 28.35; 64% *ee*, HPLC: IA, 90% hexanes, 10% ^{*i*}PrOH, 1.0 mL/min, 8.3 min (major), 10.3 min (minor); HRMS (ESI, positive) m/z calcd. for C₁₆H₂₆NO₄P [M+H]⁺ 328.1678; found 328.1669.



(*S*)-diethyl (3-oxo-1-phenyl-3-(phenylamino)propyl)phosphonate (7d): A white powder: yield 98%; $[\alpha]_D^{24} = 21^\circ$ (*c* 0.2, CH₃OH); ¹H NMR (400 MHz, CDCl₃): δ 9.68 (s, 1H, NH), 7.51 (m, 4H, Ph), 7.24 (m, 5H, Ph), 7.00 (m, 1H, Ph), 4.07 (m, 2H, CH₂), 3.96 (m, 2H, CH₂), 3.63 (m, 1H, CH), 3.30 (m, 2H, CH₂), 1.28 (t, *J* = 14.16 Hz, 3H, CH₃), 1.01 (t, *J* = 14.12 Hz, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃): δ 167.98, 138.39, 134.86, 134.79, 128.79, 128.12, 127.02, 123.06, 119.10, 62.98, 61.77, 40.09, 36.86, 15.84; ³¹P NMR (162 MHz, CDCl₃): δ 28.16; 85% *ee*, HPLC: IA, 90% hexanes, 10% ⁱPrOH, 1.0 mL/min, 11.2 min (major), 14.1 min (minor); HRMS (ESI, positive) m/z calcd. for C₁₉H₂₄NO₄P [M+H]⁺ 362.1521; found 362.1527.



(*S*)-diethyl (3-oxo-1-phenyl-3-(*o*-tolylamino)propyl)phosphonate (7e): A white solid: yield 99%; $[\alpha]_D^{24} = -22^{\circ}$ (*c* 0.3, CH₃OH); ¹H NMR (400 MHz, CDCl₃): δ 7.77 (s, 1H, NH), 7.46 (m, 3H, Ph), 7.31 (m, 4H, Ph), 7.08 (m, 3H, Ph), 4.07 (m, 2H, CH₂), 3.81 (m, 2H, CH₂), 3.62 (m, 1H, CH), 3.19 (m, 2H, CH₂), 1.94 (S, 3H, CH₃), 1.27 (d, *J* = 14.10 Hz, 3H, CH₃), 0.99 (t, *J* = 14.00 Hz, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃): δ 168.81, 135.70, 135.16, 131.41, 130.23, 129.36, 128.44, 127.38, 126.02, 125.40, 124.73, 63.12, 62.08, 41.15, 36.97, 17.55, 16.35; ³¹P NMR (162 MHz, CDCl₃): δ 27.68; 81% *ee*, HPLC: IA, 90% hexanes, 10% ^{*i*}PrOH, 1.0 mL/min, 13.4 min (major), 17.3 min (minor); HRMS (ESI, positive) m/z calcd. for C₂₀H₂₆NO₄P [M+H]⁺ 376.1678; found 376.1684.



(*S*)-diethyl (3-oxo-1-phenyl-3-(*p*-tolylamino)propyl)phosphonate (7f): A white solid: yield 99%; $[\alpha]_D^{24} = 28^{\circ}$ (*c* 0.4, CH₃OH); ¹H NMR (400 MHz, CDCl₃): δ 8.96 (s, 1H, NH), 7.46 (m, 2H, Ph), 7.33 (m, 4H, Ph), 7.22 (m,1H, Ph), 7.00 (m,2H, Ph), 4.11 (m, 2H, CH₂), 3.89 (m, 2H, CH₂), 3.63 (m, 1H, CH), 3.20 (m, 1H, CH), 2.23 (S, 3H, CH₃), 1.27 (d, *J* = 14.10 Hz, 3H, CH₃), 1.01 (t, *J* = 14.10 Hz, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃): δ 167.71, 135.79, 134.94, 132.55, 128.86, 128.62, 128.11, 127.01, 119.08, 62.96, 61.68, 40.16, 36.92, 20.31, 15.94, 15.63; ³¹P NMR (162 MHz, CDCl₃): δ 28.59; 84% *ee*, HPLC: IA, 90% hexanes, 10% ^{*i*}PrOH, 1.0 mL/min, 11.1 min

(major), 15.1 min (minor); HRMS (ESI, positive) m/z calcd. for $C_{20}H_{26}NO_4P$ [M+H]⁺ 376.1678; found 376.1689.



(*S*)-diethyl (3-((2-methoxyphenyl)amino)-3-oxo-1-phenylpropyl)phosphonate (7g): A white solid: yield 99%; $[\alpha]_D^{24} = -42^\circ$ (*c* 0.2, CH₃OH); ¹H NMR (400 MHz, CDCl₃): δ 7.76 (s, 1H, NH), 7.35 (m, 2H, Ph), 7.23 (m, 4H, Ph), 6.91 (m, 3H, Ph), 3.99 (m, 2H, CH₂), 3.79 (m, 2H, CH₂), 3.71 (s, 3H, CH₃), 3.62 (m, 1H, CH), 3.13 (m, 1H, CH), 2.94 (m, 1H, CH), 1.19 (t, *J* = 13.84 Hz, 3H, CH₃), 0.99 (t, *J* = 13.80 Hz, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃): δ 167.28, 147.27, 134.97, 128.69, 128.63, 128.13, 126.92, 123.23, 120.38, 119.32, 109.39, 62.44, 61.57, 55.08, 40.55, 38.06, 15.79; ³¹P NMR (162 MHz, CDCl₃): δ 27.85; 84% *ee*, HPLC: IA, 90% hexanes, 10% /PrOH, 1.0 mL/min, 14.8 min (major), 16.6 min (minor); HRMS (ESI, positive) m/z calcd. for C₂₀H₂₆NO₅P [M+H]⁺ 392.1627; found 392.1633.



(*S*)-diethyl (3-((4-methoxyphenyl)amino)-3-oxo-1-phenylpropyl)phosphonate (7h): A white solid: yield 99%; $[\alpha]_D^{24} = 32^\circ$ (*c* 0.4, CH₃OH); ¹H NMR (400 MHz, CDCl₃): δ 9.44 (s, 1H, NH), 7.41 (m, 2H, Ph), 7.30 (m, 2H, Ph), 7.15 (m, 3H, Ph), 6.65 (m, 2H, Ph), 3.99 (m, 2H, CH₂), 3.87 (m, 2H, CH₂), 3.62 (s, 3H, CH₃), 3.54 (m, 1H, CH), 3.19 (m, 2H, CH₂), 1.21 (t, *J* = 14.00 Hz, 3H, CH₃), 0.941 (t, *J* = 13.80 Hz, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃): δ 167.61, 138.08, 130.24, 128.24, 123.27, 119.08, 115.18, 114.97, 63.00, 61.84, 39.39, 37.99, 37.17, 15.91, 15.72; ³¹P NMR (162 MHz, CDCl₃): δ 28.61; 89% *ee*, HPLC: IA, 90% hexanes, 10% ⁱPrOH, 1.0 mL/min, 16.5 min (major), 21.5 min (minor); HRMS (ESI, positive) m/z calcd. for C₂₀H₂₆NO₅P [M+H]⁺ 392.1627; found 392.1625.



(*S*)-diethyl (3-((3-chlorophenyl)amino)-3-oxo-1-phenylpropyl)phosphonate (7i): A white solid: yield 99%; $[\alpha]_D^{24} = 55^\circ$ (*c* 0.3, CH₃OH); ¹H NMR (400 MHz, CDCl₃): δ 10.00 (s, 1H, NH), 7.45 (m, 4H, Ph), 7.22 (m, 3H, Ph), 7.01 (t, *J* = 14.08 Hz, 1H, Ph), 6.86 (d, *J* = 8.00 Hz, Ph), 4.04 (m, 2H, CH₂), 3.92 (m, 1H, CH), 3.74 (m, 1H, CH), 3.55 (m, 1H, CH), 3.25 (m, 1H, CH), 1.24 (t, *J* = 14.12 Hz, 3H, CH₃), 0.96 (t, *J* = 14.12 Hz, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃): δ 168.09, 136.68, 134.54, 133.62, 129.20, 128.76, 128.70, 128.20, 128.17, 127.15, 63.27, 61.80, 39.88, 38.48, 36.70, 15.93; ³¹P NMR (162 MHz, CDCl₃): δ 28.40; 81% ee HPLC: IA, 90% hexanes, 10% ⁴PrOH, 1.0 mL/min, 14.3 min (major), 18.0 min (minor); HRMS (ESI, positive) m/z calcd. for C₁₉H₂₃CINO₄P [M+H]⁺ 396.1131; found 396.1144.



(*S*)-diethyl (3-((4-fluorophenyl)amino)-3-oxo-1-phenylpropyl)phosphonate (7j): A white solid: yield 98%; $[\alpha]_D^{24} = 36^\circ$ (*c* 0.4, CH₃OH); ¹H NMR (400 MHz, CDCl₃): δ 9.30 (s, 1H, NH), 7.46 (m, 4H, Ph), 7.31 (m, 3H, Ph), 6.87 (t, *J* = 17.40 Hz, 2H, Ph), 4.07 (m, 2H, CH₂), 3.91 (m, 2H, CH₂), 3.63 (m, 1H, CH), 3.19 (m, 2H, CH), 1.27 (t, *J* = 14.12 Hz, 3H, CH₃), 1.01 (t, *J* = 14.12 Hz, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃): δ 167.81, 159.58, 157.17, 134.73, 134.49, 128.82, 128.14, 127.10, 120.70, 114.74, 114.52, 63.04, 61.78, 39.97, 36.71, 15.90, 0.53; ³¹P NMR (162 MHz, CDCl₃): δ 27.98; ¹⁹F NMR (376 MHz, CDCl₃): δ -118.83; 83% *ee*, HPLC: IA, 90% hexanes, 10% ¹PrOH, 1.0 mL/min, 12.8 min (major), 16.1 min (minor); HRMS (ESI, positive) m/z calcd. for C₁₉H₂₃FNO₄P [M+H]⁺ 380.1427; found 380.1426.



(*S*)-diethyl (3-oxo-1-phenyl-3-((4-(trifluoromethyl)phenyl)amino)propyl)phosphonate (7k): A white solid: yield 92%; $[\alpha]_D^{24} = 34^\circ$ (*c* 0.4, CH₃OH); ¹H NMR (400 MHz, CDCl₃): δ 9.96 (s, 1H, NH), 7.60 (m, 2H, Ph), 7.41 (m, 4H, Ph), 7.31 (m, 3H, Ph), 4.11 (m, 2H, CH₂), 3.97 (m, 2H, CH₂), 3.63 (m, 1H, CH), 3.26 (m, 2H, CH), 1.29 (t, *J* = 14.12 Hz, 3H, CH₃), 1.02 (t, *J* = 14.12 Hz, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃): δ 167.49, 138.13, 137.04, 133.92, 129.33, 128.75, 128.23, 127.28, 127.09, 123.29, 119.10, 63.04, 62.01, 39.90, 38.51, 36.65, 15.85; ³¹P NMR (162 MHz, CDCl₃): δ 28.46; ¹⁹F NMR (376 MHz, CDCl₃): δ -62.12; 77% *ee*, HPLC: IA, 90% hexanes, 10% ¹PrOH, 1.0 mL/min, 14.8 min (major), 17.8 min (minor); HRMS (ESI, positive) m/z calcd. for C₂₀H₂₃F₃NO₄P [M+H]⁺ 430.1395; found 430.1396.



(*S*)-diethyl (4-((4-methoxyphenyl)amino)-4-oxobutan-2-yl)phosphonate (7l): A white solid: yield 98%; $[\alpha]_D^{24} = 21^\circ$ (*c* 0.3, CH₃OH); ¹H NMR (400 MHz, CDCl₃): δ 9.28 (s, 1H, NH), 7.53 (m, 2H, Ph), 6.81 (m, 2H, Ph), 4.08 (m, 4H, CH₂), 3.75 s, 3H, CH₃), 2.79 (m, 1H, CH), 2.51 (m, 2H, CH₂), 1.27 (m, 12H, CH₃) ; ¹³C NMR (100 MHz, CDCl₃): δ 168.17, 155.48, 131.48, 120.81, 113.42, 61.76, 61.68, 54.95, 37.05, 27.48, 26.05, 15.92, 13.03; ³¹P NMR (162 MHz, CDCl₃): δ 34.17; 61% *ee*, HPLC: IA, 95% hexanes, 5% ^{*i*}PrOH, 1.0 mL/min, 32.3 min (major), 35.3 min (minor); HRMS (ESI, positive) m/z calcd. for C₁₅H₂₄NO₅P [M+H]⁺ 330.1470; found 330.1478.



(*S*)-diethyl (3-oxo-3-(phenylamino)-1-(*p*-tolyl)propyl)phosphonate (7m): A white solid: yield 98%; [α]_D²⁴ = 21° (*c* 0.3, CH₃OH); ¹H NMR (400 MHz, CDCl₃): δ 7.71 (s, 1H, NH), 7.47 (m, 3H, Ph), 7.31 (m, 3H, Ph), 7.10 (m, 3H, Ph), 4.07 (m, 2H, CH₂), 3.85 (m, 3H, CH), 3.62 (m, 1H, CH), 3.20 (m, 2H, CH₂), 1.94 (s, 3H, CH₃), 1.27 (t, *J* = 14.12 Hz, 3H, CH₃), 1.00 (t, *J* = 14.08 Hz, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃): δ 167.82, 138.31, 136.62, 131.70, 128.85, 128.62, 128.14, 123.07, 119.07, 62.88, 61.67, 39.71, 37.14, 20.61, 15.89; ³¹P NMR (162 MHz, CDCl₃): δ 28.04; 83% *ee*, HPLC: IA, 90% hexanes, 10% ^{*i*}PrOH, 1.0 mL/min, 8.4 min (major), 17.8 min (minor); HRMS (ESI, positive) m/z calcd. for C₂₀H₂₃NO₄P [M+H]⁺ 376.1677; found 376.1676.



(*S*)-diethyl (1-(3-chlorophenyl)-3-oxo-3-(phenylamino)propyl)phosphonate (7n): A white solid: yield 98%; $[\alpha]_D^{24} = 29^\circ$ (*c* 0.3, CH₃OH); ¹H NMR (400 MHz, CDCl₃): δ 10.01 (s, 1H, NH), 7.55 (m, 2H, Ph), 7.41 (m, 2H, Ph), 7.37 (m, 2H, Ph), 7.23 (m, 3H, Ph), 4.05 (m, 2H, CH₂), 3.90 (m, 1H, CH), 3.76 (m, 1H, CH), 3.57 (m, 1H, CH), 3.25 (m, 2H, CH₂), 1.24 (t, *J* = 14.00 Hz, 3H, CH₃), 0.97 (t, *J* = 14.00 Hz, 3H, CH₃) ; ¹³C NMR (100 MHz, CDCl₃): δ 168.29, 141.52, 134.63, 134.56, 128.76, 128.69, 128.21, 127.25, 125.38, 125.34, 118.58, 63.19, 61.79, 39.84, 36.93, 15.85; ³¹P NMR (162 MHz, CDCl₃): δ 27.76; 81% *ee*, HPLC: IA, 90% hexanes, 10% ⁱPrOH, 1.0 mL/min, 10.5 min (major), 11.8 min (minor); HRMS (ESI, positive) m/z calcd. for C₁₉H₂₃ClNO₄P [M+H]⁺ 396.1131; found 396.1143.



(*S*)-diethyl (1-(2-fluorophenyl)-3-oxo-3-(phenylamino)propyl)phosphonate (70): A white solid: yield 98%; $[α]_D^{24} = 29^\circ$ (*c* 0.3, CH₃OH); ¹H NMR (400 MHz, CDCl₃): δ 9.14 (s, 1H, NH), 7.46 (m, 3H, Ph), 7.19 (m, 3H, Ph), 7.09 (m, 3H, Ph), 4.27 (m, 13H, CH), 4.11 (m, 2H, CH₂), 3.90 (m, 1H, CH), 3.75 (m, 1H, CH), 3.24 (m, 2H, CH₂), 1.28 (t, *J* = 14.12 Hz, 3H, CH₃), 1,06 (t, *J* = 14.08 Hz, 3H, CH₃) ; ¹³C NMR (100 MHz, CDCl₃): δ 167.64, 138.25, 129.25, 128.64, 128.17, 123.75, 123.14, 122.33, 119.07, 115.29, 62.84, 62.03, 35.88, 30.86, 15.87; ³¹P NMR (162 MHz, CDCl₃): δ 27.53; ¹⁹F NMR (MHz, CDCl₃): δ -115.75; 73% *ee*, HPLC: IA, 90% hexanes, 10% ^{*i*}PrOH, 1.0 mL/min, 13.1 min (major), 15.1 min (minor); HRMS (ESI, positive) m/z calcd. for C₁₉H₂₃ClNO₄P [M+H]⁺ 380.1427; found 380.1424.



(*S*)-diethyl (1-(4-fluorophenyl)-3-oxo-3-(phenylamino)propyl)phosphonate (7p): A white solid: yield 96%; $[\alpha]_D^{24} = 29^\circ$ (*c* 0.3, CH₃OH); ¹H NMR (400 MHz, CDCl₃): δ 9.23 (s, 1H, NH), 7.44 (m, 4H, Ph), 7.19 (m, 2H, Ph), 6.99 (m, 3H, Ph), 4.08 (m, 2H, CH₂), 3.84 (m, 2H, CH), 3.64 (m, 1H, CH), 3.16 (m, 2H, CH₂), 1.28 (t, *J* = 13.88 Hz, 3H, CH₃), 1.04 (t, *J* = 13.84 Hz, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃): δ 167.61, 138.04, 130.31, 130.24, 128.24, 123.33, 119.08, 115.19, 114.97, 63.00, 61.85, 39.39, 37.17, 15.91; ³¹P NMR (162 MHz, CDCl₃): δ 27.87; ¹⁹F NMR (MHz, CDCl₃): δ -114.65; 87% *ee*, HPLC: IA, 90% hexanes, 10% ^{*i*}PrOH, 1.0 mL/min, 8.6 min (major), 17.9 min (minor); HRMS (ESI, positive) m/z calcd. for C₁₉H₂₃FNO₄P [M+H]⁺ 380.1427; found 380.1426.



(*S*)-diethyl (3-(benzyl(methyl)amino)-3-oxo-1-phenylpropyl)phosphonate (7q): A white powder: yield 99%; $[\alpha]_D^{24} = 12^{\circ}$ (*c* 0.4, CH₃OH); ¹H NMR (400 MHz, CDCl₃): δ 7.45 (m, 5H, Ph), 7.18 (m, 2H, Ph), 7.01 (m, 1H, Ph), 6.91 (m, 1H, Ph), 4.63 (m, 1H, CH), 4.33 (m, 1H, CH), 4.02 (m, 2H, CH₂), 3.85 (m, 2H, CH₂), 3.65 (m, 1H, CH), 3.06 (m, 2H, CH₂), 2.87 (m, 3H, CH₃), 1.29 (m, 3H, CH₃), 1.04 (m, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃): δ 169.64, 136.39, 135.73, 135.57, 128.90, 128.84, 128.36, 127.98, 127.16, 126.68, 125.73, 62.39, 61.39, 52.59, 50.47, 34.45, 33.29, 15.71. ³¹P NMR (162 MHz, CDCl₃): δ 28.71; 82% *ee*, HPLC: IA, 90% hexanes, 10% *'*PrOH, 1.0 mL/min, 17.5 min (major), 26.0 min (minor); HRMS (ESI, positive) m/z calcd. for C₂₁H₂₈NO₄P [M+H]⁺ 390.1834; found 390.1836.



(*S*)-diethyl (3-oxo-1-phenyl-3-(pyrrolidin-1-yl)propyl)phosphonate (7r): Colorless oil: yield 98%; $[\alpha]_D^{24} = -12^{\circ}$ (*c* 0.5, CH₃OH); ¹H NMR (400 MHz, CDCl₃): δ 7.41 (m, 2H, Ph), 7.21 (m, 2H, Ph), 7.20 (m, 2H, Ph), 4.06 (m, 2H, CH₂), 3.90 (m, 2H, CH₂), 3.71 (m, 1H, CH₂), 3.46 (m, 2H, CH₂), 3.29 (m, 2H, CH₂), 2.93 (m, 2H, CH₂), 1.77 (m, 4H, CH₂), 1.27 (t, *J* = 14.00 Hz, 3H, CH₃), 1.02 (t, *J* = 12.00 Hz, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃): δ 167.71, 135.14, 128.77, 127.83, 126.58, 62.11, 61.23, 45.99, 45.09, 40.47, 39.92, 34.94, 25.40, 23.70, 15.84; ³¹P NMR (162 MHz, CDCl₃): δ 28.57; 83% *ee*, HPLC: IB, 90% hexanes, 10% ^{*i*}PrOH, 1.0 mL/min, 14.3 min (major), 20.2 min (minor); HRMS (ESI, positive) m/z calcd. for C₁₇H₂₆NO₄P [M+H]⁺ 340.1677; found 340.1670.



(*S*)-diethyl (3-oxo-1-phenyl-3-(piperidin-1-yl)propyl)phosphonate (7s): Colorless oil: yield 95%; $[\alpha]_D^{24} = -11^{\circ}(c \ 0.3, CH_3OH)$; ¹H NMR (400 MHz, CDCl₃): δ 7.40 (m, 2H, Ph), 7.29 (m, 2H, Ph), 7.22 (m, 1H, Ph), 4.20 (m, 1H, CH), 4.07 (m, 2H, CH₂), 3.85 (m, 2H, CH₂), 3.64 (m, 1H, CH), 3.37 (m, 4H, CH₂), 3.03 (m, 2H, CH₂), 1.54 (m, 4H, CH₂), 1.36 (m, 1H, CH), 1.30 (t, *J* = 14.16 Hz, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃): δ 167.53, 135.64, 128.73, 127.89, 126.65, 62.38, 61.40, 46.09, 42.52, 40.47, 32.98, 25.08, 24.93, 23.89, 15.88; ³¹P NMR (162 MHz, CDCl₃): δ 28.52; 81% *ee*, HPLC: IA, 90% hexanes, 10% ^{*i*}PrOH, 1.0 mL/min, 12.1 min (major), 17.7 min (minor); HRMS (ESI, positive) m/z calcd. for C₂₀H₂₆NO₄P [M+H]⁺ 354.1834.1834; found 354.1832.



(S)-diethyl (3-(methyl(phenyl)amino)-3-oxo-1-phenylpropyl)phosphonate (7t): A white

powder: yield 99%; $[\alpha]_D^{24} = 13^{\circ}$ (*c* 0.3, CH₃OH); ¹H NMR (400 MHz, CDCl₃): δ 7.39 (m, 3H, Ph), 7.26 (m, 5H, Ph), 6.98 (m, 2H, Ph), 3.99 (m, 2H, CH₂), 3.85 (m, 2H, CH₂), 3.62 (m, 1H, CH), 3.13 (s, 3H, CH₃), 2.74 (m, 2H, CH₂), 1.24 (t, *J* = 11.80, 3H, CH₃), 1.00 (t, *J* = 12.64 Hz, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃): δ 169.40, 142.88, 135.27, 129.34, 128.80, 127.84, 127.52, 126.81, 126.70, 62.22, 61.28, 40.76, 39.36, 34.08, 15.62; ³¹P NMR (162 MHz, CDCl₃): δ 28.22; 80% *ee*, HPLC: IA, 90% hexanes, 10% 'PrOH, 1.0 mL/min, 12.2 min (major), 13.5 min (minor); HRMS (ESI, positive) m/z calcd. for C₂₀H₂₆NO₄P [M+H]⁺ 376.1678; found 376.1691.

The ¹H, ¹³C, ³¹P NMR spectra and HPLC spectrum of compound 7a



120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -50 -50 -70 -80 -90 -100 -110 -120 f1 (ppm)





<Peak Table> PDA Ch1 190nm

PDA C	n1 190nm			
Peak#	Ret. Time	Area	Height	Area%
1	13.237	18754291	756127	50.665
2	19.456	18261859	396363	49.335
Total		37016150	1152491	100.000

PDA	C	n1 190nm			
Peal	<#	Ret. Time	Area	Height	Area%
	1	12.150	44417129	2012266	92.432
	2	17.739	3636701	114843	7.568
Tot	tal		48053830	2127109	100.000

The ¹H, ¹³C, ³¹P NMR spectra and HPLC spectrum of compound **7b**



30 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -13i ff(gpm)





7.5

E.

PDA C	h1 190nm			
Peak#	Ret. Time	Area	Height	Area%
1	7.873	2767793	211621	49.352
2	8.566	2840521	194689	50.648
Total		5608314	406310	100.000

10.0

12.5

15.0 min

DAC				
Peak#	Ret. Time	Area	Height	Area%
1	7.901	2476822	191862	87.293
2	8.650	360560	25214	12.707
Total		2837382	217076	100.000



The ¹H, ¹³C, ³¹P NMR spectra and HPLC spectrum of compound 7c





PDA C	h1 190nm	-		14
Peak#	Ret. Time	Area	Height	Area%
1	8.346	15749529	970693	49.493
2	10.209	16072338	827254	50.507
Total		31821867	1797947	100.000

PDA C	h1 190nm			
Peak#	Ret. Time	Area	Height	Area%
1	8.327	16058262	995204	82.370
2	10.340	3437024	201272	17.630
Total		19495287	1196476	100.000





120 110 100 90 80 70 60 50 40 30 20 10 0 10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -13(ff(gpm)



<Peak Table> PDA Ch1 254nm

<Peak Table> PDA Ch1 254nm

PDA C	n i 254nm			
Peak#	Ret. Time	Area	Height	Area%
1	11.338	245232	12227	50.001
2	14.200	245226	10126	49.999
Total		490458	22353	100.000

-DA C	111 2341111			
Peak#	Ret. Time	Area	Height	Area%
1	11.278	4091396	218525	92.499
2	14.196	331795	14287	7.501
Total		4423191	232813	100.000



The ¹H, ¹³C, ³¹P NMR spectra and HPLC spectrum of compound **7e**





h1 220nm			
Ret. Time	Area	Height	Area%
13.529	10988786	454221	50.071
17.174	10957694	376720	49.929
	21946480	830941	100.000
	n1 220nm Ret. Time 13.529 17.174	n1 220nm Ret. Time Area 13.529 10988786 17.174 10957694 21946480	11 220nm Ret. Time Area Height 13.529 10988786 454221 17.174 10957694 376720 21946480 830941

<Peak Table> PDA Ch1 254nm

DAC	111 23411111			
Peak#	Ret. Time	Area	Height	Area%
1	13.482	6389968	259291	90.380
2	17.361	680149	23571	9.620
Total		7070117	282862	100.000

The $^1\text{H},\,^{13}\text{C},\,^{31}\text{P}$ NMR spectra and HPLC spectrum of compound 7f



120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 f1(ppm)



h1 254nm			
Ret. Time	Area	Height	Area%
10.971	32233860	1653709	49.053
14.694	33478552	1334206	50.947
	65712412	2987915	100.000
	h1 254nm Ret. Time 10.971 14.694	h1 254nm Ret. Time Area 10.971 32233860 14.694 33478552 65712412	h1 254nm Ret. Time Area Height 10.971 32233860 1653709 14.694 33478552 1334206 65712412 2987915

PDA C	n1 254nm			
Peak#	Ret. Time	Area	Height	Area%
1	11.114	46793676	2126617	92.004
2	15.157	4066915	170506	7.996
Total		50860590	2297123	100.000

The $^1\text{H},\,^{13}\text{C},\,^{31}\text{P}$ NMR spectra and HPLC spectrum of compound $\mathbf{7g}$







PDA C	n1 254nm			
Peak#	Ret. Time	Area	Height	Area%
1	15.093	8075670	309046	49.894
2	16.770	8110131	282406	50.106
Total		16185801	591452	100.000

<Peak Table> PDA Ch1 254nm

FUAU	111 2341111			
Peak#	Ret. Time	Area	Height	Area%
1	14.719	17279210	661482	92.320
2	16.638	1437375	53621	7.680
Total		18716585	715102	100.000

The 1 H, 13 C, 31 P NMR spectra and HPLC spectrum of compound **7h**



130 120 110 100 50 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -110 -120 ff (ppm)





PDA Ch1 254nm				
Ret. Time	Area	Height	Area%	
16.406	18320092	624710	50.162	
21.067	18201600	490926	49.838	
	36521692	1115636	100.000	
	h1 254nm Ret. Time 16.406 21.067	h1 254nm Ret. Time Area 16.406 18320092 21.067 18201600 36521692	h1 254nm Ret. Time Area Height 16.406 18320092 624710 21.067 18201600 490926 36521692 1115636	

DAC	111 2341111			
Peak#	Ret. Time	Area	Height	Area%
1	16.518	42674289	1397341	94.459
2	21.551	2503483	69881	5.541
Total		45177772	1467221	100.000









Peak# Ret. Time Area	Height	Area%
1 9.404 91685	67 632358	49.698
2 10.622 92801	09 568753	50.302
Total 184486	75 1201111	100.000

Peak#	Ret. Time	Area	Height	Area%
1	9.850	3960781	258539	90.991
2	11.166	392137	25305	9.009
Total		4352918	283844	100.000



The ¹H, ¹³C, ³¹P, ¹⁹F NMR spectra and HPLC spectrum of compound 7j





PDAC	n i 254nm	01	2	5
Peak#	Ret. Time	Area	Height	Area%
1	9.055	2108739	93287	49.939
2	12.161	2113896	78597	50.061
Total		4222635	171885	100.000

<Peak Table>
PDA Ch1 254nm
Peak# Ret. Time
1 12.860

DA C	h1 254nm		21.21.21.21.2	- 14 A 4 7
eak#	Ret. Time	Area	Height	Area%
1	12.860	540350	26782	91.641
2	16.123	49290	2013	8.359
Total		589640	28795	100.000







10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210





PDA C	h1 254nm			
Peak#	Ret. Time	Area	Height	Area%
1	15.070	11679986	506366	49.981
2	17.969	11688789	426735	50.019
Total		23368775	933101	100.000

PDA C	h1 220nm		12042 - 1777 I	11505 12222
Peak#	Ret. Time	Area	Height	Area%
1	14.887	11364708	493945	88.868
2	17.798	1423556	53374	11.132
Total	1	12788263	547319	100.000

The $^1\text{H},\,^{13}\text{C},\,^{31}\text{P}$ NMR spectra and HPLC spectrum of compound 71



130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 11(ppm)





<Peak Table> PDA Ch1 254nm Peak# Ret. Time 1 33.592 2 36.036 Total Area 3750953 3805525 7556478 Height 70784 65061 135844 Area% 49.639 50.361 100.000 Total

<Peak Table> PDA Ch1 254nm

	111 2341111			
eak#	Ret. Time	Area	Height	Area%
1	32.290	14634434	256779	80.306
2	35.349	3588956	59035	19.694
Total		18223390	315815	100.000
	eak# 1 2 Total	eak# Ret. Time 1 32.290 2 35.349 Total	eak# Ret. Time Area 1 32.290 14634434 2 35.349 3588956 Total 18223390	Contract Contract Area Height 1 32.290 14634434 256779 2 35.349 3588956 59035 Total 18223390 315815





130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -110 -120 f1(ppm)





PDA C	h1 190nm			
Peak#	Ret. Time	Area	Height	Area%
1	8.553	9967646	751619	49.847
2	17.832	10029018	355304	50.153
Total		19996665	1106922	100.000

DICO	2041111			
Peak#	Ret. Time	Area	Height	Area%
1	8.497	15986596	1120462	91.595
2	17.881	1466941	50885	8.405
Total		17453537	1171347	100.000



The ¹H, ¹³C, ³¹P NMR spectra and HPLC spectrum of compound 7n

^{. . .} 140 120 -20 -40 -60 f1 (ppm) -160 -190 -220 100 80 60 40 20 0 -80 -130



PDA C	h1 254nm			
Peak#	Ret. Time	Area	Height	Area%
1	10.570	497163	29780	49.652
2	11.826	504137	27173	50.348
Total		1001300	56953	100.000

<Peak Table> PDA Ch1 254nm

PDAC	n i 254nm			
Peak#	Ret. Time	Area	Height	Area%
1	10.553	822059	49243	90.556
2	11.830	85729	4696	9.444
Total		907789	53939	100.000



The ¹H, ¹³C, ³¹P, ¹⁹F NMR spectra and HPLC spectrum of compound **70**

^{120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120} ff (ppm)



0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -110 -130 -150 -170 -190 -210 -230 -250 -270 -290 ft (pm)





<Peak Table>

PDA C	n1254nm			
Peak#	Ret. Time	Area	Height	Area%
1	13.243	426383	19706	49.877
2	15.248	428490	17530	50.123
Total		854873	37236	100.000

PDA C	h1 254nm			
Peak#	Ret. Time	Area	Height	Area%
1	13.126	49646	2115	86.850
2	15.110	7517	334	13.150
Total		57163	2449	100.000







10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 ff (ppm)



<Peak Table>

PDA C	h1 254nm			
Peak#	Ret. Time	Area	Height	Area%
1	8.627	4271617	300672	49.514
2	17.926	4355498	153682	50.486
Total		8627115	454353	100.000

PDA C	h1 254nm			
Peak#	Ret. Time	Area	Height	Area%
1	8.613	3905938	278263	93.730
2	17.914	261299	9400	6.270
Total		4167237	287662	100.000





120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 ft (ppm)





PDA C	h1 190nm			
Peak#	Ret. Time	Area	Height	Area%
1	17.388	24219035	730454	49.676
2	24.443	24535241	300211	50.324
Total		48754276	1030665	100.000

<Peak Table> PDA Ch1 190nm

	111 1901111			
Peak#	Ret. Time	Area	Height	Area%
1	17.575	7672711	242357	91.110
2	26.075	748651	14444	8.890
Total		8421362	256801	100.000



The $^1\text{H},\,^{13}\text{C},\,^{31}\text{P}$ NMR spectra and HPLC spectrum of compound 7r



<Peak Table> PDA Ch1 190nm

PDA C	n1 190nm			
Peak#	Ret. Time	Area	Height	Area%
1	15.172	7938487	177318	49.126
2	20.571	8220883	119456	50.874
Total		16159370	296774	100.000

PDA Ch1 190nm						
Peak#	Ret. Time	Area	Height	Area%		
1	14.354	18294018	407946	91.515		
2	20.287	1696070	30957	8.485		
Total		19990088	438903	100.000		









PDA Ch1 190nm						
Peak#	Ret. Time	Area	Height	Area%		
1	14.303	21516225	490351	49.412		
2	19.109	22028437	314112	50.588		
Total		43544662	804463	100.000		

<peak t<="" th=""><th>able></th></peak>	able>
PDA Ch1	190nm

0/10				
Peak#	Ret. Time	Area	Height	Area%
1	14.007	37140563	789874	90.762
2	19.947	3780457	67579	9.238
Total		40921020	857453	100.000

The ¹H, ¹³C, ³¹P NMR spectra and HPLC spectrum of compound 7t





 Peak Table>
 Peak Table>

 PDA Ch1 254nm
 PDA Ch1 254nm

 Peak#Ret.Time
 Area

 1
 12.364
 466019
 21929
 49.631

 2
 13.502
 472954
 19930
 50.369
 2
 13.520

 Total
 938973
 41859
 100.000
 Total
 Total

PDA C	h1 190nm			
Peak#	Ret. Time	Area	Height	Area%
1	12.283	30382339	1944414	90.292
2	13.520	3266483	152046	9.708
Total		33648822	2096460	100.000
	PDA C Peak# 1 2 Total	PDA Ch1 190nm Peak# Ret. Time 1 12.283 2 13.520 Total	PDA Ch1 190nm Peak# Ret. Time Area 1 12.283 30382339 2 13.520 3266483 Total 33648822	PDA Ch1 190nm Peak# Ret. Time Area Height 1 12.283 30382339 1944414 2 13.520 3266483 152046 Total 33648822 2096460

The HPLC spectrum of compound 7a after recrystallization



The HPLC spectrum of single crystal of 7a



<p< th=""><th>eak</th><th>Та</th><th>b</th><th>e></th></p<>	eak	Та	b	e>
-				-

PDA Ch1 190nm						
Peak#	Ret. Time	Area	Height	Area%		
1	12.073	19809722	762808	98.795		
2	18.244	241560	8038	1.205		
Total		20051283	770846	100.000		

PDA Ch1 190nm						
Peak#	Ret. Time	Area	Height	Area%		
1	12.229	3568854	156292	100.000		
Total	11.40.	3568854	156292	100.000		







^{230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10}

Reference:

[1] (a) C. Zeng, D. Yuan, B. Zhao, Y. Yao, *Organic Letters*, 2014, **17**(9), 2242-2245.
[2] (a) S. Yang, T. Kang, C. Rui, X. Yang, Y. Sun, Z. Cui, Y. Ling, *Chin. J. Chem.*, 2011, **29**(11), 2394-2400. (b) S. Ueda, T. Okada, H. Nagasawa, *Chem. Commun.*, 2010, **46**(14), 2462-2464. (c)

C.-W. Chan, P.-Y. Lee, W.-Y. Yu, Tetrahedron Letters, 2015, 56(20), 2559-2563. (d) W. Dong, Y.

Liu, B. Hu, K. Ren, Y. Li, X. Xie, Y. Jiang, Z. Zhang, Chem. Commun., 2015, 51(22), 4587-4590.